BioNTech SE’s Post

NEWS OF THE DAY! Breakthrough: AbbVie's $10 Billion ImmunoGen, Inc. Deal Clinches FDA Approval for Ovarian Cancer Drug!   1. FDA grants full approval for AbbVie's drug Elahere for ovarian cancer treatment 2. Drug approved for folate receptor alpha-positive, platinum-resistant epithelial ovarian cancer patients with up to three prior therapies 3. Elahere developed by ImmunoGen, initially received accelerated approval in November 2022 4. Full approval based on data from Phase 3 study MIRASOL 5. AbbVie acquired ImmunoGen for approximately $10 billion in February =>Please follow Finplate and stay updated with the latest #mergersandacquisitions news. Thanks in advance. To read the news in detail, click below: https://lnkd.in/gRnyjBEd

Part III: Exploring 2023's Breakthroughs: Phase 2 Oncology Clinical Trials Uncovered #clinicaltrials #oncology In this part, lets deep dive into Phase 2 oncology trials of 2023 which uncovers significant progress and insights, spotlighting the pharmaceutical industry's dedication towards addressing a wide range of cancer challenges. #AdvancedSolidTumor emerges as a primary focus, leading in the number of trials underscoring the industry’s commitment to comprehensive cancer care. The trials for #BreastCancer and #NonSmallCellLungCancer follow closely, reflecting precise endeavors to tackle some of the most widespread and lethal cancers, impacting millions globally. The diversity in research focus underscores a holistic approach to oncology, aiming to leave no stone unturned in the quest for cures.   But this data also prompts us to think beyond what's being researched. What are your thoughts on how can we leverage #emergingtechnologies to not only fill these gaps but also accelerate the path from trials to treatment?  Do let me know your insights and thoughts. #medicalinnovations #healthcaretrends #pharmaceuticalindustry #cancerresearch #clinicaltrials #medicalinnovation Source: www.clinicaltrials.gov

Excited to attend the FDA Oncology Center of Excellence (OCE) Conversations on Cancer webinar this afternoon. Discussion will focus on the most transformative oncology drug approvals for 2023, and feature a diverse panel of speakers including patients, advocates, clinical investigators, and practitioners who will address: ☑️Patient and investigator perspectives on their experiences with these drugs, including importance of timely access. ☑️Patient perspectives on the impact of these drugs on their cancer prognosis and quality of life. ☑️Investigators’ perspectives on the impact of these drugs on their respective cancer landscape and treatment paradigm for the specified cancer indication(s).  ☑️Barriers to access of these newly approved drugs and ways to help overcome these barriers. #oncologyresearch #cancerresearch #patientexperience #advocacymatters #drugdevelopment

Daiichi Sankyo reports results from HERTHENA-Lung01 Phase II trial Out of the total patients, 225 participants who received patritumab deruxtecan 5.6 mg/kg showed an ORR of 29.8%. Daiichi Sankyo, Inc. has reported data from the HERTHENA-Lung01 Phase II trial of patritumab deruxtecan (HER3-DXd) for the treatment of EGFR-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC). The international, two-arm, open-label, multicentre study enrolled patients from Oceania, Asia, North America, and Europe. Daiichi Sankyo Research and Development global head Ken Takeshita said: “The results from HERTHENA-Lung01, coupled with early trial results, show that patritumab deruxtecan demonstrates clinically meaningful and durable responses, illustrating the potential of this HER3 directed antibody drug conjugate to become a new standard of care for this patient population with high unmet medical need. “These data will support our ongoing discussions with health authorities including our planned submission in the US.” News Story in comments: #clinicaltrials #phaseII #DaiichiSankyo

The Phase Ib study (NCT04894825) of FutureGen Laboratories’s FG-M108 combined with chemotherapy in advanced pancreatic cancer shows promise. With 46 patients treated, the 300 mg/m³ dose had a 33.3% ORR and the 600 mg/m³ dose had a 30% ORR, both achieving a 100% DCR. Despite all patients experiencing TEAEs, the safety profile is favorable. Further evaluation of PFS and OS will determine long-term benefits. Unlock In-Depth Expert Insights and Analysis with DelveInsight Business Research LLP's Exclusive American Society of Clinical Oncology (ASCO) 2024 Reporting: https://lnkd.in/gWptYZp2 #ASCO24 #CancerTreatment #ASCO2024 #LungCancer #NSCLC #mCRPC #PharmaInnovation #MedicalResearch #OncologyAdvancements #ClinicalOncology #Pharmaceuticals #HealthcareConference #CancerResearch #ClinicalPractice #MedicalBreakthroughs #CancerCare #PharmaLeaders

GSK today announced positive headline results from a planned analysis of Part 1 of the RUBY/ENGOT-EN6/GOG3031/NSGO phase III trial investigating #Jemperli (#dostarlimab) plus standard-of-care chemotherapy (carboplatin and paclitaxel), followed by dostarlimab as a single agent, compared to placebo plus chemotherapy followed by placebo in adult patients with primary advanced or recurrent endometrial cancer. The trial met its primary endpoint of overall survival (OS), demonstrating a statistically significant and clinically meaningful benefit in the overall patient population. Hesham A. Abdullah, MD, MSc, SVP, Global Head Oncology, R&D, #GSK, said: “With today’s headline results from Part 1 of the phase III RUBY trial, dostarlimab plus chemotherapy has become the only immuno-therapy combination to show a survival benefit in this broader patient population in this treatment setting. We look forward to sharing detailed results of this analysis with regulatory authorities and the larger scientific community.” Full results from this latest analysis from the trial will be published in a medical journal and presented at an upcoming scientific meeting. #oncology #endometrialcancer #clinicaltrials #RUBYtrial #immunotherapy  For more information 👉 https://lnkd.in/d6G8nDrW

⚕️Access to healthcare, including cancer care, is a fundamental human right. Yet, cancer remains a complex and difficult disease to treat – and not all patients are receiving the care they need. This #WorldCancerDay 2024 (February 4th), we’re highlighting the unique opportunities that #cannabidiol may present as a possible anti-cancer therapy and anti-sickness medicine. In our latest science-led blog, we investigate the evidence behind the molecule as a potential treatment for lung and breast cancer and uncover how research and development in the space is helping to “close the care gap”. https://bit.ly/3vXC9tr #cannabinoids #APIs #pharmaceuticals #drugdevelopment #CancerCareForAll #CloseTheCareGap #dsmfirmenichPharma

This content is for US audiences only. Along with Daiichi Sankyo US, we announced high-level overall survival results from the TROPION-Lung01 Phase III trial of our investigational TROP2-directed antibody drug conjugate for patients with advanced nonsquamous non-small cell lung cancer (NSCLC). At AstraZeneca, we’re not ones to shy away from challenging the status quo when it comes to standard of care. This news marks the first time in more than a decade that a therapeutic approach beyond immune checkpoint inhibitors has prolonged the survival of patients with nonsquamous NSCLC in this advanced setting compared to the standard of care chemotherapy. Building on positive progression-free survival data, these results will support our ongoing discussions with the FDA to potentially bring a much-needed new option to eligible patients in need. Read more about the announcement:https://bit.ly/3WY4bk3 #USOnly #AstraZenecaUS

The Phase Ib study (NCT04894825) of FutureGen Laboratories’s FG-M108 combined with chemotherapy in advanced pancreatic cancer shows promise. With 46 patients treated, the 300 mg/m³ dose had a 33.3% ORR and the 600 mg/m³ dose had a 30% ORR, both achieving a 100% DCR. Despite all patients experiencing TEAEs, the safety profile is favorable. Further evaluation of PFS and OS will determine long-term benefits. Unlock In-Depth Expert Insights and Analysis with DelveInsight Business Research LLP's Exclusive American Society of Clinical Oncology (ASCO) 2024 Reporting: https://lnkd.in/g83UCHtx #ASCO24 #CancerTreatment #ASCO2024 #LungCancer #NSCLC #mCRPC #PharmaInnovation #MedicalResearch #OncologyAdvancements #ClinicalOncology #Pharmaceuticals #HealthcareConference #CancerResearch #ClinicalPractice #MedicalBreakthroughs #CancerCare #PharmaLeaders

Our collaboration with Acrivon Therapeutics, Inc. continues to progress and create new hope for those affected by ovarian, endometrial, and bladder cancer. In case you missed it, the ACR-368 OncoSignature Assay, which incorporates Akoya’s PhenoImager HT instrument and multiplex immunofluorescence technology, was granted Breakthrough Device designation by the FDA in November. This designation highlights the potential of the assay, along with the Akoya technologies that underlie it, in identifying ovarian cancer patients who may benefit from treatment with ACR-368. Acrivon was additionally granted two Fast Track designations for the investigation of ACR-368 as a monotherapy last year. These designations are based on ACR-368 OncoSignature-predicted sensitivity in patients with platinum-resistant ovarian and endometrial cancer. These Fast Track designations will expedite the development and regulatory review of ACR-368, facilitating its potential availability to patients in need. Learn how the ACR-368 OncoSignature Assay marks a significant advancement in identifying patients suitable for a targeted oncology agent, potentially ushering in a new era of precision medicine: https://bit.ly/45RVDvN #spatialbiology #precisionmedicine #spatialproteomics #oncology